What is the pathophysiology of hyperosmolar hyperglycemic state (HHS) in type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Hyperosmolar Hyperglycemic State (HHS)

Core Metabolic Mechanism

HHS results from relative insulin deficiency combined with elevated counterregulatory hormones, but unlike DKA, residual insulin action remains sufficient to prevent significant ketogenesis while being inadequate to control hyperglycemia. 1, 2

The fundamental pathophysiologic cascade involves:

  • Insulin deficiency (relative, not absolute) triggers excessive hepatic glucose production and impaired peripheral glucose uptake, leading to progressive hyperglycemia that typically exceeds 600 mg/dL 1, 2
  • Residual insulin activity suppresses lipolysis and ketogenesis, explaining why ketones remain minimal or absent (≤3.0 mmol/L) and pH stays ≥7.30—the key distinction from DKA 1, 2
  • Counterregulatory hormone elevation (cortisol, catecholamines, glucagon, growth hormone) further amplifies hepatic glucose output and peripheral insulin resistance 3, 4

Progressive Dehydration and Hyperosmolarity

The hallmark of HHS is severe osmotic diuresis leading to profound volume depletion (100-220 mL/kg or approximately 9 liters total body water deficit) and marked hyperosmolarity (≥320 mOsm/kg). 1, 5

The dehydration cascade unfolds as follows:

  • Marked hyperglycemia (≥600 mg/dL) exceeds the renal threshold for glucose reabsorption, causing massive osmotic diuresis 1, 2
  • Osmotic water loss far exceeds electrolyte losses, resulting in hypernatremia and rising effective osmolality calculated as: 2[Na+ (mEq/L)] + glucose (mg/dL)/18 1
  • Hypovolemia reduces glomerular filtration rate, creating a vicious cycle where impaired renal glucose clearance worsens hyperglycemia 3, 6
  • Prerenal azotemia develops from decreased renal perfusion 3

Age-Related Vulnerability

Elderly patients are particularly susceptible to HHS due to physiologic changes that impair compensatory mechanisms. 3, 7

Key age-related factors include:

  • Reduced glomerular filtration rate and elevated renal threshold for glucose prevent adequate osmotic diuresis correction of hyperglycemia 7
  • Impaired thirst mechanisms fail to trigger appropriate fluid intake despite severe dehydration 7
  • Increased insulin resistance in muscle and adipose tissue, compounded by abdominal obesity and elevated free fatty acids 3
  • Blunted glucose-induced insulin release from pancreatic beta cells 3
  • Elevated inflammatory markers (TNF-α, IL-6) that worsen insulin resistance 3

Timeline of Development

HHS evolves gradually over days to weeks, fundamentally different from DKA which develops over hours to days. 1, 2, 8

The prolonged timeline reflects:

  • A precipitating illness (infection most common) triggers the cascade in a patient with type 2 diabetes 1, 5
  • Progressive hyperglycemia and osmotic diuresis develop over several days 1
  • Polyuria, polydipsia, and weight loss precede mental status changes by days 1
  • The gradual evolution allows more severe dehydration and higher osmolality than typically seen in DKA 8

Neurological Consequences

Altered mental status correlates directly with the degree of hyperosmolarity and occurs more frequently in HHS than DKA, ranging from lethargy to stupor/coma. 1, 2

The neurological impact results from:

  • Hyperosmolarity-induced cellular dehydration in the central nervous system 1, 6
  • Osmotic shifts that impair neuronal function proportional to effective osmolality 6
  • Mental obtundation severity directly correlates with osmolality levels ≥320 mOsm/kg 1

Systemic Effects of Hyperglycemia

Acute hyperglycemia causes multiple detrimental effects beyond osmotic diuresis. 3

These include:

  • Impaired leukocyte function with decreased phagocytosis, bacterial killing, and chemotaxis, predisposing to infections and poor wound healing 3
  • Activation of NF-κB and production of proinflammatory cytokines, leading to oxidative stress 3
  • Increased vascular permeability and mitochondrial dysfunction 3
  • Endothelial dysfunction through suppressed nitric oxide formation and impaired flow-mediated dilation 3

Common Precipitating Factors

Infection is the most common trigger, but multiple factors can precipitate HHS by increasing insulin requirements or impairing glucose control. 1, 5

Major precipitants include:

  • Infections (pneumonia, urinary tract infections, sepsis) are the leading cause 1, 5
  • Cardiovascular events (myocardial infarction, stroke) particularly in elderly patients 1, 5
  • Medications affecting carbohydrate metabolism: thiazide diuretics, corticosteroids, SGLT2 inhibitors, sympathomimetic agents, beta-blockers 3, 1, 5
  • Non-adherence to diabetes therapy or newly diagnosed diabetes 1, 5

Critical Pitfall to Avoid

Do not assume HHS requires altered mental status—patients meeting metabolic criteria (glucose ≥600 mg/dL, osmolality ≥320 mOsm/kg) warrant HHS management even if fully alert. 1 The absence of mental status changes does not exclude HHS diagnosis when other criteria are met, and delayed recognition increases the 15% mortality rate 1, 2.

References

Guideline

Hyperosmolar Hyperglycemic State Diagnostic Criteria and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hyperosmolar Hyperglycemic State (HHS) and Diabetic Ketoacidosis (DKA) Key Differences

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diabetic Ketoacidosis Causes and Risk Factors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hyperosmolar syndrome in a patient with uncontrolled diabetes mellitus.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001

Research

Diabetic non ketotic hyperosmolar state: a special care in aged patients.

Archives of gerontology and geriatrics, 1996

Related Questions

What is the role of insulin in the management of Hyperosmolar Hyperglycemic State (HHS) in older adults with type 2 diabetes and impaired renal function?
What are the immediate management goals for a patient with hyperglycemic hyperosmolar nonketotic syndrome (HHNS)?
What is the recommended acute management for an adult patient with a blood glucose concentration above 20 mmol/L?
How can I diagnose Hyperosmolar Hyperglycemic State (HHS) in a patient with a history of diabetes who presents to the office?
What is the best management approach for an elderly female patient with insulin-dependent diabetes mellitus (IDDM), Alzheimer's disease, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure with Reduced Ejection Fraction (HFrEF), hypertension, and a history of cardiac catheterization, presenting with hyperosmolar hyperglycemic non-ketotic coma (HHS), severe hyperglycemia, and elevated serum osmolality?
What is the recommended rate for titrating gabapentin, and how should the schedule be adjusted in older adults or patients with renal impairment?
Which of the following factors requires warfarin rather than a direct‑acting oral anticoagulant (DOAC) for secondary stroke prevention: pregnancy, obesity (BMI 35 kg/m²), bioprosthetic mitral valve, moderate rheumatic mitral stenosis, or end‑stage renal disease?
In a generally healthy adult seeking an over‑the‑counter supplement for sleep, is melatonin or γ‑aminobutyric acid (GABA) the preferred choice, and what are the recommended dosing and safety considerations?
In a generally healthy reproductive‑age woman without clotting medication use, hormone‑sensitive cancer, uncontrolled thyroid disease, or severe liver/kidney disease, is Proov Pro supplement safe and appropriate for luteal‑phase support to improve implantation?
What is the recommended management for hyperkalemia in a patient with a serum potassium of 6.5 mEq/L and ECG changes (or 6.0–6.5 mEq/L without ECG changes)?
What is the maximum recommended duration of phentermine therapy for a patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.